Kaken Pharmaceutical Co., Ltd. (TSE: 4521)
Health Care · Pharmaceuticals · JP
¥3,705.00
-1.85% today · +0.1% 1Y
Kaken Pharmaceutical Co., Ltd. (TSE: 4521) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $886.07M and employs 1,114 people.
Over the last twelve months the share price has gained 0.1%, trading between 3.54K and 4.45K.
Tweenvest scores Kaken Pharmaceutical Co., Ltd. across four factors: quality 76/100, value 65/100, growth 0/100, dividend 100/100. Its strongest factor is dividend.
4521 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $886.07M
- Revenue (TTM)
- $542.37M
- P/E
- 13.61
- EPS
- 272.32
- Dividend yield
- 5.13%
- Beta (5Y)
- 0.12
- 52-week high
- ¥4,445.00
- 52-week low
- ¥3,540.00
- Avg volume (3M)
- —
- Shares outstanding
- 37.87M
- Employees
- 1,114
- Next earnings
- —
About Kaken Pharmaceutical Co., Ltd.
Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensive product portfolio includes specialized treatments like Clenafin, a topical solution for fungal nail infections; Artz, an agent combating osteoarthritis; Seprafilm, an absorbable film preventing surgical adhesions; Fiblast, a spray designed for pressure and skin ulcer healing; Regroth for periodontal tissue regeneration; and Hernicore, which addresses lumbar disc herniation. They also market Adofeed, a plaster for pain and inflammation relief; Ebrantil for dysuria and hypertension management; Procylin, an oral prostaglandin I2 analogue; Lipidil, used to treat high cholesterol; Mentax, an anti-fungal cream; and Loxoprofen Na Tape, another pain-relieving and anti-inflammatory patch. Additionally, Ropion is offered as an injectable pain medication. The company's agricultural and animal health division provides products such as Polyoxins, a fungicidal agent; Pentoxazone, a herbicide for rice crops; and Salinomycin, an anti-coccidial feed additive for poultry. Kaken Pharmaceutical is actively advancing several investigational compounds. BBI-4000 has completed its Phase III clinical trials for primary axillary hyperhidrosis, while KMW-1 is also in Phase III for managing eschar removal in thermal burns. KAR is being developed for hide lice infestation, and KP-607 is currently in Phase II for the treatment of onychomycosis. Beyond pharmaceuticals, the firm also manages the rental of the commercial property, Bunkyo Green Court. Its products are sold under various brand names, including Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia. The company holds licensing agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Established in 1917, Kaken Pharmaceutical Co., Ltd. has its main office situated in Tokyo, Japan.
- ISIN
- JP3207000005
- Founded
- 1917
- Listed since
- Jan 1, 2001
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Hainan Haiyao Co., Ltd.SZSE: 000566 | $912.29M | CN¥4.71 | +1.95% |
| Bide Pharmatech Co., Ltd.SHSE: 688073 | $906.79M | CN¥70.50 | -7.96% |
| Procter & Gamble Health LimitedBSE: 500126 | $894.55M | Rs5,215.55 | +1.12% |
| Youcare Pharmaceutical Group Co., Ltd.SHSE: 688658 | $887.89M | CN¥13.38 | -4.70% |
| Luye Pharma Group Ltd.SEHK: 2186 | $880.59M | HK$1.73 | -5.46% |
| Mega Lifesciences Public Company LimitedSET: MEGA | $876.99M | ฿33.75 | -2.88% |
| Chongqing Lummy Pharmaceutical Co., Ltd.SZSE: 300006 | $862.31M | CN¥5.47 | -1.62% |
| Helus Pharma Inc.NasdaqGM: HELP | $862.11M | $11.31 | -4.15% |
Figures last refreshed Oct 11, 2026.